10 more meds for diabetes, cancer, other illnesses added to VAT-free list
Under FDA Advisory No. 2025-0510 dated June 4, the FDA included two medicines for cancer, two for diabetes, one for high cholesterol, two for hypertension, and three for mental illness.
For cancer, the medicines included in the VAT exemption are:
Tegafur + Gimeracil + Oteracil Potassium capsule (20 mg/5.8 mg/19.6 mg)
Tegafur + Gimeracil + Oteracil Potassium capsule (25 mg/7.25 mg/24.5 mg)
For diabetes, the following medicines are exempted:
Metformin Hydrochloride + Teneligliptin extended-release tablet (as hydrobromide hydrate) (1 g/20 mg)
Metformin Hydrochloride + Teneligliptin extended release tablet (as hydrobromide hydrate) (500 mg/20 mg)
The following is included for high cholesterol:
Atorvastatin (as calcium) + Fenobribrate film-coated tablet (20 mg/160 mg)
For hypertension, the following medicines are included:
Metoprolol tartrate + Ivabradine film-coated tablet (as hydrochloride) (50 mg/5 mg)
Metoprolol tartrate + Ivabradine film-coated tablet (as hydrochloride) (25 mg/5 mg)
Meanwhile, the following are the medicines included for mental illnesses:
Lamotrigine dispersible/chewable tablet (5 mg)
Lamotrigine oral dispersible tablet (25 mg)
Lamotrigine tablet (25 mg)
Meanwhile, the FDA removed the medicine Baricitinib (2 mg and 4 mg) for cancer from the list. —Joahna Lei Casilao/AOL, GMA Integrated News
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
GMA Network
6 days ago
- GMA Network
US health experts to reassess hormone replacement therapy risks
HRT is taken to replace estrogen the body stops producing after menopause -- when periods end permanently -- and helps relieve symptoms such as hot flashes and vaginal discomfort. WASHINGTON - US health authorities are set Thursday to reassess Hormone Replacement Therapy (HRT), a treatment used by menopausal women around the world but long clouded by debate over its risks. HRT is taken to replace estrogen the body stops producing after menopause -- when periods end permanently -- and helps relieve symptoms such as hot flashes and vaginal discomfort. But its use has plummeted in recent years amid concerns over rare side effects, including a potential link to invasive breast cancer. Food and Drug Administration (FDA) chief Marty Makary, who convened Thursday's meeting of outside experts, has long advocated for HRT, saying its risks have been overstated. "For decades, hormone replacement therapy for women -- that is estrogen or estrogen plus progesterone -- has helped women alleviate the symptoms of menopause, including hot flashes, dryness, mood swings, weight gain and poor sleep quality, to name a few," he said in a video. He added that when initiated within a decade of the onset of the transitional period before menopause, HRT may even reduce cognitive decline, the risk of Alzheimer's, and prevent osteoporosis and cardiovascular disease. Makary blamed the drop in HRT use on a landmark clinical trial, the Women's Health Initiative, which was halted in the early 2000s after it flagged increased risks of breast cancer and stroke. But he said subsequent studies had not replicated the findings on breast cancer. Critics of the trial argue it was flawed because the participants were too far from menopause, and that the formulations used are now outdated. Still, the issue remains divisive within the medical community. The FDA's own warning label for HRT -- which can be administered through various means including orally, through skin patches, or vaginally -- cites risks including endometrial cancer, breast cancer, and life-threatening blood clots. This week, the American Journal of Physicians published an editorial that found limited benefits and significant harms associated with HRT. "Menopause is a positive life experience for many women and should not be medicalized," the authors concluded. The nature of the FDA expert meeting is also unusual. Unlike standard practice before the Trump administration, no agenda was publicly posted. Several of the named panelists have ties to companies offering menopause treatments or who belong to the advocacy group "Let's Talk Menopause," which receives funding from pharmaceutical companies and campaigns to revise the FDA warning label. — Agence France-Presse
GMA Network
01-07-2025
- GMA Network
FDA: Dengue, ASF vaccines still pending approval
The Food and Drug Administration (FDA) said Tuesday they are still processing the approval of vaccines intended to counter Dengue and African Swine Fever. During an ambush interview on Tuesday, FDA Director General Paolo Teston said they are still waiting for several required documents for post-approval from the applicants of the ASF vaccine. 'Nag-uundergo po siya ng post-approval commitment compliance po ng naaprubahan po na una ng FDA. Marami pa pong submission requirements po… Ang FDA naman po ay patuloy na naghihintay sa submissions, sa pagsusumite ng nabigyan po ng monitored release ng certificate of product registration (CPR),' he shared. (It is undergoing post-approval commitment compliance when it was initially approved by the FDA. There are still a lot of submission requirements… The FDA continues to wait for submissions for those granted with monitored release of the CPR.) Teston said that compliance with the needed submissions may be enough for a CPR, but that applicants would still need to comply with post-approval commitments. He added the ASF vaccine is undergoing scrutiny from the FDA's fact-finding committee. 'Sana po pwede ko sabihin na yesterday yung timeline namin [ng approval], pero ang FDA po talaga ang concern niya is health and safety ng mga produkto. We cannot compromise po yung safety ng produkto na gagamitin sa ating livestock, particularly sa mga baboy po, para lang po mapabilis yung proseso,' he said. (I hope I could say that our timeline [of approval] was yesterday, but the FDA's concern is the health and safety of these products. We cannot compromise the safety of the product that will be used on our livestock, particularly on pigs, just to speed up the process.) Teston said should applicants be able to properly submit all necessary documents, the vaccine should be approved within the year. 'Kailangan lang din po namin sagutin yung ibang issue kasama yung pre-approval na natanong po nung nagkaroon po ng inquiry sa Congress about dito sa ASF vaccine,' he said. (We just have to address the other issues, including the pre-approval that had been raised during a Congress inquiry about the ASF vaccine.) Meanwhile, Teston shared that TAC-003 or QDenga vaccine against dengue is now being assessed by an FDA expert panel. The QDenga vaccine is an live-attenuated vaccine with an 80% first year post-vaccination efficacy against Virologically Confirmed Dengue (VCD) fever, recommended for prevention of the disease in people who had never been infected and had already been approved in more than 40 countries with over 10 million doses distributed nationwide. 'Ito ay sumasailalim sa pagsusuri ng expert panel both po ng FDA at pati expert panel ng external ng FDA,' he said. (This is undergoing an investigation from the FDA's expert and external expert panels.) 'Independent po kasi yung expert panel ng FDA dahil sila po yung nakakaalam, sila po yung nag-aassure ng quality and safety and efficacy ng produkto, lalo na pag bago yung produkto,' Teston added. (The FDA expert panel is independent because they are the ones whom understand, and they are the ones that assure the quality and safety and efficacy of the product, especially if the product is new.) The FDA notes that approvals of the vaccine undergo a whole of government approach and acknowledged the urgent need of both vaccines to combat the spread of Dengue and ASF in the country. 'Ina-acknowledge po naman natin yung need for the vaccine and relatively po, fina-facilitate po siya ng FDA as long as there are no standards violated and the safety of the Filipinos who will be inoculated with the vaccine will be assured… Sana pwede ko din sabihin na yesterday yung lead time [sa release ng bakuna], pero sa lalong madaling panahon po sana [ma-approve na],' Teston said. (We are acknowledging the need for the vaccine and relatively, the FDA is facilitating it as long as there are no standards violated and the safety of the Filipinos who will be inoculated with the vaccine will be assured… I hope I can also say that the lead time [fpr the release of the vaccine] was yesterday, but I hope it [gets approved] as soon as possible.) —RF, GMA Integrated News
GMA Network
28-06-2025
- GMA Network
Herbosa cites Dengvaxia lesson as PH mulls approval of Qdenga vaccine
Department of Health Secretary Teodoro Herbosa said the government was evaluating whether to introduce the Qdenga vaccine in the Philippines to prevent dengue in children. The Food and Drug Administration has been reviewing the application of Japan-based Takeda Pharmaceuticals for a certificate of product registration (CPR) for Qdenga since 2023. 'We will not use the Qdenga as a mass-based immunization. It has to be done in your clinics because what we've learned from Dengvaxia was that you should know the serologic status of the person you're giving the dengue vaccine to. So, it's very important that you take a serologic test [to measure antibodies in the blood] before you decide to give any of these new dengue vaccines,' Herbosa said during the 2nd Dengue Summit organized by the Philippine Medical Association on Wednesday. In 2023, Herbosa said that he had no plans to reintroduce Dengvaxia due to controversies surrounding the vaccine. This followed after the manufacturer against prescribing Dengvaxia to patients who have not had the virus in the past, since it may cause severe diseases in the long run. Dengvaxia was even linked to the deaths of Filipino children, but the Department of Justice withdrew the criminal charges against former Health Secretary Janette Garin and several others early this year for lack of adequate grounds for conviction. Research Institute for Tropical Medicine—Research and Innovative Office head Dr. Charissa Borja-Tabora said the World Health Organization recommends the use of Qdenga in children aged 6 to 16 years in settings with high dengue transmission. 'The vaccine is recommended as a two-dose schedule with a minimum interval of three months between doses,' she said. Borja-Tabora added that further innovations and research are being conducted for more effective treatment and prevention of dengue. This includes additional vaccines in development, as well as antibody therapies for passive immunization. 'Vaccines provide direct individual protection against dengue infection, and critically, significantly reduce the risk of dengue hospitalization. And, of course, if you're able to immunize a certain number or percentage in the community, then you also decrease the amount of virus circulating in the community,' she said. According to DOH, the Philippines recorded 119,000 dengue cases as of May 31, up 59% compared to the period from January to May 2024. A total of 470 dengue-related deaths were also recorded in the first five months of the year. — VBL, GMA Integrated News
